Novo Nordisk and Microsoft Collaborate to Accelerate Drug Discovery Through AI

By Dominic Chopping

Danish pharmaceutical company Novo Nordisk AS said Monday that it has entered a new strategic collaboration with Microsoft Corp. that seeks to accelerate drug discovery and development by using big data and artificial intelligence.

Through the partnership, Microsoft is providing AI technology, foundational science models and expertise and is working alongside Novo Nordisk's data scientists and domain experts to accelerate Novo Nordisk's research and development.

AI models arising from the collaboration will be applied to a range of use case, with the first two already in execution, it said.

"Together, we are on a path to enable faster and scaled use of AI in drug discovery, ultimately leading to more breakthrough innovations and efficiency gain to better serve the needs of patients," Lars Fogh Iversen, Novo Nordisk's senior vice president of digital science & innovation, said.

Write to Dominic Chopping at [e-mail]

(END) Dow Jones Newswires

09-12-22 0727ET